---
title: "OrbiMed Advisors Discloses Investment at Electra Therapeutics with 11.0% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300167793.md"
description: "OrbiMed Advisors LLC disclosed an 11.0% stake in Electra Therapeutics, Inc., following its IPO and preferred share conversion. Filed on September 25, 2026, the investment is for portfolio purposes, with no intent to acquire control or initiate corporate actions. OrbiMed agreed to a 180-day lock-up period post-IPO but retains registration rights for future resale."
datetime: "2026-09-25T21:36:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300167793.md)
  - [en](https://longbridge.com/en/news/300167793.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300167793.md)
generator: "portal-rs"
---

# OrbiMed Advisors Discloses Investment at Electra Therapeutics with 11.0% Stake

OrbiMed Advisors LLC disclosed an 11.0% stake in Electra Therapeutics, Inc. common stock. The filing, dated September 25, 2026, follows Electra Therapeutics’ IPO and the conversion of preferred shares into common stock. The position reflects a significant life sciences investor taking a meaningful post-IPO stake.

**Investor Intent**

OrbiMed states it bought the shares for investment and "not with the intention of acquiring control" of Electra Therapeutics. The firm says it has no current plans for mergers, asset sales, board changes, or other corporate actions, but it may buy or sell shares in the future.

The group agreed to a 180-day lock-up after the IPO, saying it will "not sell or offer to sell" its shares during that period, subject to limited exceptions. OrbiMed and affiliated funds also hold registration rights that allow them to request future public resale registrations after IPO lock-up windows expire and other conditions are met.

**Investor's Background**

OrbiMed Advisors LLC is a Delaware limited liability company and a registered investment adviser focused on healthcare and life sciences. The firm invests globally across venture capital, private equity, and public equities in biotechnology, pharmaceuticals, and medical devices. OrbiMed is known for backing drug development companies through late-stage clinical milestones and for active engagement with boards.

Original SEC Filing: Electra Therapeutics, Inc. \[ ETRA \] - SCHEDULE 13D - Sep. 25, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ETRA.US](https://longbridge.com/en/quote/ETRA.US.md)

## Related News & Research

- [OrbiMed Advisors acquires 1,333,333 Electra Therapeutics shares for USD 20 million](https://longbridge.com/en/news/299946121.md)
- [HBM Healthcare Investments says Electra Therapeutics IPO raises USD 350 million](https://longbridge.com/en/news/299591426.md)
- [Alphabet Inc. $GOOG Shares Acquired by Kwmg LLC](https://longbridge.com/en/news/301171695.md)
- [LIVE MARKETS-TSMC earnings could cause another round of consensus upgrades](https://longbridge.com/en/news/301145455.md)
- [Palantir vs. Oracle – Why Daniel Ives Says Buy One, Hold the Other](https://longbridge.com/en/news/301155464.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**